Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;10(18):6167-6188.
doi: 10.1002/cam4.4192. Epub 2021 Aug 10.

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?

Bailong Liu  1 , Hui Liu  1 , Yunfei Ma  1 , Qiuhui Ding  1 , Min Zhang  1 , Xinliang Liu  1 , Min Liu  1
Affiliations
Review

EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?

Bailong Liu et al. Cancer Med. 2021 Sep.

Abstract

Lung cancer is the leading cause of cancer-related death globally and poses a considerable threat to public health. Asia has the highest prevalence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Despite the reasonable response and prolonged survival associated with EGFR-tyrosine kinase inhibitor (TKI) therapy, the acquisition of resistance to TKIs remains a major challenge. Additionally, patients with EGFR mutations are at a substantially higher risk of brain metastasis compared with those harboring wild-type EGFR. The role of radiotherapy (RT) in EGFR-mutated (EGFRm) stage IV NSCLC requires clarification, especially with the advent of next-generation TKIs, which are more potent and exhibit greater central nervous system activity. In particular, the feasible application of RT, including the timing, site, dose, fraction, and combination with TKI, merits further investigation. This review focuses on these key issues, and provides a flow diagram with proposed treatment options for metastatic EGFRm NSCLC, aiming to provide guidance for clinical practice.

Keywords: EGFR mutation; TKI; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors made no disclosures.

Figures

FIGURE 1
FIGURE 1
Preliminary treatment outlines for driver oncogene‐positive NSCLC with brain metastases. ALK, anaplastic lymphoma kinase; BM, brain metastasis; EGFR, epidermal growth factor receptor; NSCLC, non‐small cell lung cancer; PD, progressive disease; ROS1, c‐Ros oncogene 1 receptor tyrosine kinase; SIB, simultaneous integrated boost; SRS, stereotactic radiosurgery; TKI, tyrosine kinase inhibitor; WBRT, whole‐brain radiotherapy
FIGURE 2
FIGURE 2
Pooled survival results from retrospective studies in this review mentioned about the effect of first‐ or second‐generation EGFR‐TKI combined with cranial RT before progression. iPFS ranges from 8.1 to 25 months,, , , , , , , , and OS ranges from 14.3 to 48 months., , , , , , , , EGFR: epidermal growth factor receptor; iPFS, intracranial progression‐free survival; RT, radiotherapy; TKI, tyrosine kinase inhibitor
FIGURE 3
FIGURE 3
The EGFR signaling pathway is involved in irradiation (IR)‐induced DNA damage repair. ATM, ataxia telangiectasia mutation; ATR, ataxia‐telangiectasia and RAD3‐related; BER, base excision repair; DNA‐PKcs, DNA‐dependent protein kinase catalytic subunit; EGFR, epidermal growth factor receptor; ERK, extracellular‐regulated protein kinase; GSK3β; glycogen synthase kinase 3 beta; HR, homologous recombination; LEF‐1, lymphoid enhancer factor 1; MEK, mitogen‐activated extracellular signal‐regulated kinase; NHEJ, non‐homologous end joining; PARP, poly ADP‐ribose polymerase; PCNA, proliferating cell nuclear antigen; PI3K, phosphatidylinositol 3‐kinase; XRCC, x‐ray repair complementing defective repair in Chinese hamster cells
FIGURE 4
FIGURE 4
Flow diagram with therapeutic options in EGFR‐mutated stage IV NSCLC. BM, brain metastasis; ChT, chemotherapy; CR, complete remission; EGFR, epidermal growth factor receptor; NGS, next‐generation sequencing; NSCLC, non‐small cell lung cancer; PD, progressive disease; PR, partial remission; RP, radiation pneumonitis; RT, radiotherapy; SD, stable disease; SRS, stereotactic radiosurgery; TKI, tyrosine kinase inhibitor; TRT, thoracic radiotherapy; WBRT, whole‐brain radiotherapy
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. - PubMed
    1. Cho BC, Chewaskulyong B, Lee KH, et al. Osimertinib versus standard of care EGFR TKI as first‐line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J Thorac Oncol. 2019;14(1):99‐106. - PubMed
    1. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non‐small cell lung cancer: a systematic review and meta‐analysis. Oncotarget. 2016;7(48):78985‐78993. - PMC - PubMed
    1. Li LN, Luo SM, Lin H, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non‐small cell lung cancer. J Thorac Dis. 2017;9(8):2510‐2520. - PMC - PubMed
    1. Iuchi T, Shingyoji M, Itakura M, et al. Frequency of brain metastases in non‐small‐cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol. 2015;20(4):674‐679. - PubMed

Publication types

MeSH terms